Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BYSIBullishCorporate Developmentsnews

High materiality8/10

FDA Fast Track for Plinabulin+Docetaxel; China funding advances DUBLIN-4

Sep 29, 2026, 7:06 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Fast Track can accelerate development interactions; non-dilutive China funding mitigates cash burn; interim DUBLIN-4 readout could drive value if favorable.

AI summary

What happened, with direct paths to the underlying reporting

BeyondSpring (BYSI) secures FDA Fast Track for Plinabulin+docetaxel in post-ICI NSCLC and strikes a non-dilutive Chinese funding deal with Biolin to support the China portion of DUBLIN-4, reducing cash burn while preserving global enrollment of 442 patients. The interim analysis at 221 PFS events represents a near-term catalyst that could unlock a valuation inflection if results are favorable.

FDA grants Fast Track for Plinabulin+docetaxel in 2L-3L NSCLC.
BeyondSpring to sell majority stake in Chinese subsidiary to Biolin.
China portion of DUBLIN-4 to be funded by Biolin; ~221 patients enrolled in China.
Global DUBLIN-4 aims for 442 patients; interim analysis at 221 PFS events.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.